Balyasny Asset Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Balyasny Asset Management’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,625,235	Closed	-$56.3M	–	3099
2026 Q1	$56.3M	Buy	2,625,235 +1,135,311	+76%	+$16M	0.07%	311
2025 Q4	$13.9M	Buy	1,489,924 +105,877	+8%	+$885K	0.02%	884
2025 Q3	$9.76M	Buy	+1,384,047	New	+$9.52M	0.01%	1068
2025 Q2	–	Sell	-133,641	Closed	-$1.06M	–	2926
2025 Q1	$1.06M	Buy	133,641 +104,186	+354%	+$1.12M	﹤0.01%	1963
2024 Q4	$373K	Buy	+29,455	New	+$410K	﹤0.01%	2300
2024 Q2	–	Sell	-53,152	Closed	-$878K	–	2663
2024 Q1	$878K	Buy	53,152 +37,547	+241%	+$562K	﹤0.01%	1847
2023 Q4	$228K	Buy	+15,605	New	+$189K	﹤0.01%	2272
2023 Q1	–	Sell	-9,883	Closed	-$213K	–	2747
2022 Q4	$213K	Buy	+9,883	New	+$203K	﹤0.01%	2116

Other funds holding DAWN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Balyasny Asset Management's DAWN Position: Q2 2026 in Review

Balyasny Asset Management sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 2,625,235 shares — an estimated $56.3M sold.

Balyasny Asset Management first reported a position in DAWN in Q4 2022 and held it in 8 quarters. The position peaked at $56.3M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.

Balyasny Asset Management reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
Balyasny Asset Management sold 2,625,235 Day One Biopharmaceuticals shares in Q2 2026, an estimated $56.3M.
Balyasny Asset Management first reported a position in Day One Biopharmaceuticals in Q4 2022 and held it in 8 quarters.
Balyasny Asset Management's Day One Biopharmaceuticals position peaked at $56.3M in Q1 2026.
1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.